Seroatlas · Human Serome Atlas

MYADM

Myeloid-associated differentiation marker

Also known as: MYADM_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q96S97
Gene: MYADM
Ensembl: ENSG00000179820
Chromosome: 19
Canonical length: 322 aa
Protein class: Predicted membrane proteins, Transporters
Subcellular location: Nuclear speckles

OverviewNCBI Gene

Involved in several processes, including negative regulation of actin filament polymerization; negative regulation of heterotypic cell-cell adhesion; and positive regulation of substrate adhesion-dependent cell spreading. Located in several cellular components, including cortical actin cytoskeleton; membrane raft; and ruffle. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

322 residues, UniProt reviewed canonical sequence.

>Q96S97|MYADM
     1  MPVTVTRTTI TTTTTSSSGL GSPMIVGSPR ALTQPLGLLR LLQLVSTCVA FSLVASVGAW
    61  TGSMGNWSMF TWCFCFSVTL IILIVELCGL QARFPLSWRN FPITFACYAA LFCLSASIIY
   121  PTTYVQFLSH GRSRDHAIAA TFFSCIACVA YATEVAWTRA RPGEITGYMA TVPGLLKVLE
   181  TFVACIIFAF ISDPNLYQHQ PALEWCVAVY AICFILAAIA ILLNLGECTN VLPIPFPSFL
   241  SGLALLSVLL YATALVLWPL YQFDEKYGGQ PRRSRDVSCS RSHAYYVCAW DRRLAVAILT
   301  AINLLAYVAD LVHSAHLVFV KV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against MYADM can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 8
Mean surface accessibility (rSASA): 0.3
Highest tissue expression: 210 nTPM

Expression across tissuesHPA

Tissue

endometrium: 210 nTPM
bone marrow: 185 nTPM
blood vessel: 178 nTPM
smooth muscle: 169 nTPM
adipose tissue: 168 nTPM
colon: 142 nTPM

Single-cell type

neutrophils: 531 nCPM
mast cells: 427 nCPM
fallopian secretory cells: 385 nCPM
extravillous trophoblasts: 364 nCPM
hepatic stellate cells: 362 nCPM
smooth muscle cells: 318 nCPM

Immune cell

neutrophil: 208 nTPM
eosinophil: 166 nTPM
basophil: 74 nTPM
myeloid DC: 60 nTPM
classical monocyte: 48 nTPM
intermediate monocyte: 27 nTPM

Brain region

midbrain: 93 nTPM
choroid plexus: 92 nTPM
hypothalamus: 87 nTPM
basal ganglia: 83 nTPM
cerebral cortex: 83 nTPM
white matter: 78 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.42
gnomAD pLI: 0.01
gnomAD missense Z: 0.66
DepMap mean gene effect: -0.04
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of MYADM in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

TGFBR2

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads MYADM as an antibody target. Whether an autoantibody or antibody against MYADM could matter depends on whether native MYADM is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

MYADM is annotated at the cell surface, where native MYADM is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label MYADM as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...